The decision by Novo Nordisk to discontinue the insulin pens will force patients to revert to syringes, complicating diabetes care for millions of people.

Novo Nordisk, which manufactures weight-loss drug Wegovy and diabetes medication Ozempic, has asked the US authorities to ...

The company, headquartered in the key swing state of Pennsylvania, has announced the creation of 330 jobs in a significant ...

A research team in China has held atoms in a state of quantum superposition for 23 minutes, suggesting tantalizing new ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Better known by Novo Nordisk's brand names Ozempic and Wegovy (the former of which is indicated only for type 2 diabetes), ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

The effects last only for a few hours. Examples include exenatide and lixisenatide. Ozempic: Novo Nordisk’s name-brand ...